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INTRODUCTION
Pituitary adenomas are generally considered as
benign tumors, however about 30% of them behave
aggressively such as cavernous sinus invasion (1-3).
In such case, the tumor recurrence may be seen in
a short period after operation, therefore, prediction
of biologic behavior is important for therapeutic
planning of this tumor. 201Tl chrolide (201Tl-Cl) single-
photon emission computed tomography (SPECT)
has been reported to be useful to detect tumor
viability in malignant tumors (4, 5). Nakano et al .
(6) demonstrated that invasive pituitary adenomas
exhibited higher 201Tl-Cl uptake indices on both
the early and the delayed images, and that 201Tl-Cl
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uptake index on delayed image correlated with
MIB-1 labeling index (LI) in pituitary adenomas.
Technetium-99m sestamibi (99mTc-MIBI) have
been considered a potential tumor imaging agent
for detecting various kinds of cancer including brain
tumor. Several investigators demonstrated that 99mTc-
MIBI uptake correlated with histological malig-
nancy or proliferative potential in gliomas (7-9). In
addition, P-glycoprotein (Pgp), which is encoded by
mutidrug resistance gene 1 (MDR1), recognizes cer-
tain chemotherapeutic agents as a substrate and
prevents accumulation of some lipophilic cationic
radiopharmaceuticals such as 99mTc-MIBI (10-14).
Retention of 99mTc-MIBI is reduced in cells with a
multidrug-resistant phenotype because of increased
expression of the energy-dependent Pgp efflux
pump, which expels the substrates from the cell
(9, 12). Previous studies have shown an inverse
relationship between the levels of Pgp and the bal-
ance of 99mTc-MIBI uptake and washout rates in
tumor cells (9, 10, 12). However, little is known
about such features of 99mTc-MIBI SPECT in pitui-
tary adenomas.
The present study evaluated whether 99mTc-MIBI
SPECTmight correlate with cavernous sinus invasion,
proliferative potential, or Pgp expression, as en-
coded by the multidrug resistance gene-1 (MDR-1)
messenger ribonucleic acid (mRNA), in pituitary
adenomas (24, 25).
MATERIALS AND METHODS
We studied 15 patients with pituitary adenoma
who were surgically treated in our hospital be-
tween April 1998 and December 2001. 99mTc-MIBI
SPECT were performed preoperatively on 15 patients
(five men, 10 women, age range from 25 to 68 yrs,
mean age 47.7 yrs). For this study, an explanation
of its objects and methodology was performed to
all patients and their families. The tumor samples
were classified by histological subtype according
to hormone production ; they included 10 non-
functioning adenomas, 2 prolactinomas, 2 GH pro-
ducing adenomas, one ACTH producing adenoma.
A portion of each tumor was sanap-frozen immedi-
ately after resection by immersion into nitrogen and
fixed in formalin fixative for paraffin embedding.
Cavernous sinus invasion by tumor was defined
on the basis of MRI findings, and was determined
as invasion in whose grade is higher than 2 of the
classification by Knosp et al (15).
99mTc-MIBI SPECT Imaging
Isotope imaging was performed with a fan-beam
collimater and a triple head gamma camera (Picker
Prism 3000; Picker International, Cleaveland, OH).
This camera was interfaced with a dedicated com-
puter (ODYSSEY ; Picker International). Patients
were given doses of 600 MBq 99mTc-MIBI injected
intraveneously. Early SPECT acquisition was per-
formed 15 minutes after the injection of each ra-
dioisotope, whereas delayed SPECT images were
acquired 3 hours after injection. Three energy ana-
lyzers were used for acquisition, and these were
set at 140-KeV with 15% window for 99mTc images.
These projection data were processed with a two-
dimensional low-pass filter, then corrected for con-
tamination scatter. Transverse, coronal, and sagittal
sections were reconstructed. The systemwas 7.2mm
full width at half maximum, and the slice thickness
was 6.88 mm. In order to eliminate such contami-
nation scatter, the raw 99mTc data were corrected
according to the equations in each pixel. SPECT
images were compared with brain magnetic reso-
nance (MR) images, and accumulation in pituitary
adenomas was evaluated by the same radiologist.
Semiquantitative analysis of abnormal uptake of
the two radiopharmaceuticals was performed by
drawing identical regions of interest (ROIs) over
the tumor uptake area and the normal brain on
one transverse section that demonstrated the le-
sion most clearly, which region was carefully se-
lected on both early and delayed images. The
mean ROI values (total counts/ total pixels) were
measured, and the tumor-to-normal brain (T/N)
ratios were obtained. The T/N ratio of the early
images was called the early ratio (ER), and theT/N
ratio of delayed image was called the delayed ratio
(DR). For semiquantitative evaluation of the degree
of retention in the lesion, the retention index (RI)
was calculated using the following formula : (DR-
ER)/ER×100%.
Immunnohistochemistry
Pgp expression was evaluated immunohisto-
chemically on formalin-fixed, paraffin-embedded
sections using monoclonal antibodies (MAbs) against
Pgp (JSB-1, Progen Biotechnik, Heiderberg, Ger-
many). Proliferative potentials were examined us-
ing MIB-1 MAb (Immunotech, Marseille, France)
against Ki-67 antigen by means of the streptavidin-
biotin method.
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Six-micron sections were deparaffinized in xylene,
rehydrated through graded alcohols, and immersed
for 15 minutes in phosphate-buffered saline (PBS).
For antigen retrieval, the sections were micro-
waved in a 0.01 M citrate buffer (pH 6.0) for 20
minutes. After microwave pretreatment, the endo-
genous peroxidase activity was blocked by immer-
sion in a 3% hydrogen peroxidase/methanol solu-
tion for 10 minutes, and nonspecific staining was
then blocked by a 20-minute incubation with normal
horse serum. The sections were then incubated
overnight at 4℃ with primary antibodies (JSB-1,
1 : 50 dilution ; MIB-1, 1 : 50 dilution) in a humidity
chamber. The sections were treated for 30 minutes.
with biotinylated horse secondary antibody against
mouse immunoglobulins (ABC Elite, Vector Lab.,
Burlingame, Calfornia, U. S. A.) and for 30 minutes.
with avidin-biotin complex (ABC Elite), followed
by 0.06% diaminobenzidine with 0.01% hydrogen
peroxidase for 5 minutes. The slides were lightly
counterstained with hematoxylin. Control groups
were obtained by omitting the primary antibody.
The tumors were classified into two groups ac-
cording to the degree of Pgp immunostaining as
follows: Tumors that had no staining or less than 5%
of specimens were referred to as “-” ; those with
diffuse positivity and dense or moderate staining
were referred to as “+”
The MIB-1 LI was calculated as the percentage
of tumor cells that tested MIB-1 positive. More
than 500 tumor cells in randomly chosen micro-
scopic fields were examined, and the percentage
of MIB-1 positive cells was calculated.
Reverse transcription-polymerasechainreaction (RT-PCR)
Total RNA was isolated from the frozen tissue
sample using ISOGEN reagent (Nippon Gene,
Toyama, Japan). In brief, 100mg of each tissue
was homogenized in 1ml of ISOGEN. Subsequently,
0.2 ml of chloroform was added and the mix was
centrifuged. This separated the solution into an
aqueous phase containing RNA, an interphase con-
taining DNA, and an organic phase containing pro-
tein. The aqueous layer was aspirated and added
to 0.5 ml of isopropanol for RNA precipitation. Fol-
lowing this, the solution was centrifuged, then the
pellet was washed with 75% ethanol and centri-
fuged. Afterward, RNA was collected into 50 µl of
diethylpyrocarbonate (DEPC)-treated water. RT-PCR
was performed using a First-Strand cDNA Synthe-
sis Kit (Amarsham Pharmacia Biotech, Woerden,
The Netherlands). One microliter of total RNA (1µg)
was added to 14 l of RT-mixture. After mixing, the
samples were incubated at 37℃ for 45 minutes, 95℃
for 5 minutes, and 4℃ for at least 5 minutes. We
synthesized two oligodeoxynucleotide primers with
the sequences 5’-GCCTGGCAGCTGGAAGACAA
ATACACAAATT-3’ and 5’- CAGACAGCAGCTGACA
GTCCAACAACAGGACT-3’ for MDR-1 (16), and 5’- A
TCACCATTGGCAATGAGCG -3’ and 5’-TTGAAGG
TAGAAACGTGGAT-3’ for β actin. Thirty five mi-
croliters of a PCR-mixture containing 10nM prim-
ers and Taq DNA polymerase (Amershan Pharma-
cia Biotech) was added to the RT-products. Initial
denaturation for 2 minutes at 94℃ was followed by
30 cycles of 1 minute at 94℃, 1 minutes at 55℃, 2
minutes at 72℃, and a final extension for 6 min-
utes at 72℃. The PCR-products were separated on
2% agarose gels, and ethidium bromide-stained bands
were recorded by Mupid-2 R (Cosmo-Bio, Tokyo,
Japan). The expressed sizes of the PCR products
were 283 bp for MDR-1 and 93 bp for β actin.
Statistical analysis
Correlations among the factors were evaluated
using Pearson correlation coefficient (r). The values
of the each T/N ratio and RI were expressed as the
mean ± standard error. To test for differences be-
tween these parameters, the Student’s t-test was
used. Correlation was analyzed using the Pearson
Product moment test and linear regression. Results
were considered significant at the level of p<0.05.
RESULTS
Among the 15 cases with pituitary adenomas, all
were macroadenomas (more than 10mm diame-
ter), and five cases showed cavernous sinus invasion.
The clinical, 99mTc-MIBI SPECT, and immunohis-
tochemical data are summarized in Table 1.
All cases showed positive uptake on both ER and
DR for 99mTc-MIBI SPECT (Fig. 1). No correlation was
found on the ER, DR, RI of the 99mTc-MIBI SPECT
among the functional type of pituitary adenomas.
The results of Pgp immunohistochemistry are
also summarized in Table 1. Positive reactions for
Pgp were detected, mainly in the cytoplasm of tumor
cells, in 6 of 15 (40%) pituitary adenomas (Fig. 2).
In five cases out of 15 pituitary adenomas, the
expression of MDR-1 mRNA was investigated by
RT-PCR assay. RT-PCR products were visualized
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with ethidium bromide, which clearly showed the
band of interest (293 bp) (Fig. 3). The expression
of MDR-1 mRNA was clearly seen in 2 of 5 (40%)
specimens by RT-PCR assay. Two cases with MDR-1
mRNA overexpression and one of three cases with
no MDR-1 mRNA expression showed positive Pgp
immunoreactivity, whereas other two cases with
no MDR-1 expression were negative for Pgp. This
result indicated that Pgp levels were increased ac-
cording to the expression of MDR-1 mRNA, and
that Pgp may be regulated through MDR-1 mRNA
expression.
Neither ER, DR, nor RI on 99mTc-MIBI SPECT
correlated with MIB-1 LI.
The RI (-38.55±20.77%) on 99mTc-MIBI SPECT of
cases with Pgp positive expression was signifi-
cantly lower than that (-15.78±19.40%) of cases
without Pgp expression (p=0.0494) (Table 2). The
ER or DR on 99mTc-MIBI SPECT did not correlate
with Pgp expression (Table 2).
Fig. 1 : Neuroimaging findings in a 42-year-old male with non-
functioning pituitary adenoma. Postcontrast T1-weighted corenal
magnetic resonance image (A) shows a tumor in the pituitary
region. Both early (B) and delayed (C) images of technetium-
99m sestamibi single photon emission computed tomography
show an intense accumulation corresponding to the lesion.
Fig. 2 : Photomicrograph showing positive immunohisto-
chemical reactivity for P-glycoprotein, diffusely in the cyto-
plasm and nulceus of tumor cells. Original magnification × 200
Table 1. Clinical, single photon emission computed tomography(SPECT), imunohistochemical, and molecular biological charac-
teristics of 15 patients
Case
No.
Age
(yr)
Sex Size
(mm)
Cavernous
invasion
99mTc-MIBI-SPECT
Pgp
MDR -1
mRNA
MIB-1
LI (%) FunctionER DR RI(%)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
52
65
42
46
30
25
42
68
53
25
36
64
52
66
50
F
M
F
M
F
F
M
M
M
F
F
F
F
F
F
13×15
35×32
23×24
10×11
12×10
10×10
30×28
25×20
21×19
10×10
10×12
24×20
25×25
20×18
25×22
－
－
－
－
－
－
－
－
－
－
＋
＋
＋
＋
＋
42.65
143.70
13.93
13.00
51.55
19.22
15.46
47.53
57.79
20.75
36.38
17.13
115.81
8.52
185.83
28.48
99.22
7.75
10.00
11.55
15.00
18.00
42.79
55.83
17.57
37.75
13.11
71.55
5.80
111.75
－33.2
－31.0
－44.4
－23.1
－77.6
－22.0
16.4
－10.0
－3.4
－15.3
3.8
－23.5
－38.2
－31.9
－39.9
＋
＋
＋
＋
＋
＋
－
－
－
－
－
－
－
－
－
＋
－
＋
n.d.
n.d.
n.d.
－
n.d.
－
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
2.6
2.2
0.9
0.1
0.1
0.0
2.5
2.1
1.3
1.0
0.1
1.5
0.5
0.1
0.8
GH
NF
NF
GH
PRL
NF
NF
NF
NF
NF
ACTH
NF
NF
NF
PRL
ER : early ratio, DR : delayed ratio, RI : retention index, LI : labeling index, n.d. : not done,
NF : nonfunctioning adenoma, PRL : prolactin producing adenoma, GH : growth hormone producing adenoma,
ACTH : adorenocorticotropic hormone producing adenoma, Pgp : P-glycoprotein,
99mTc-MIBI-SPECT : technetium-99m-methoxyisobutylisonitrile single photon emission computed tomography
Fig. 3 : Ethidium bromide-stained agarose gel showing re-
verse transcription-polymerase chain reaction analysis of mul-
tidrug resistance gene-1 (MDR-1) mRNA expression (293 bp)
in pituitary adenomas (upper line). Two of five cases showing
overexpression of MDR-1 mRNA. The lower line representsβ actin,
which was used as a control.
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DISCUSSION
201Tl-Cl -SPECT, which is useful for diagnosing a
variety of tumors, and also for evaluating the de-
gree of malignancy or proliferative potential in brain
tumors (4, 5, 17-21), is available for detecting bio-
logical aggressiveness such as cavernous invasion
or proliferative potential in pituitary adenomas, to
determine the indication for surgical treatment
(6). On the other hand, 99mTc-MIBI SPECT are
also useful to evaluate the histological grade or
proliferative potential in gliomas (7, 8, 22, 23). How-
ever, there are few reports regarding the relation-
ship between 99mTc-MIBI SPECT findings and
proliferative potential or cavernous invasion in pi-
tuitary adenomas (24, 25). Our study revealed that
99mTc-MIBI SPECT findings do not correlate with
either MIB-1 LI or cavernous sinus invasion in
pituitary adenomas.
99mTc-MIBI uptake is reported to distribute to
normal structures of choroid plexus and the pitui-
tary gland (9). Kojima et al. (24)suggested that 99mTc-
MIBI was not taken up in the normal pituitary
gland but in the dorsum sellae or clivus, whereas
they evaluated the uptake of 99mTc-MIBI in mi-
croadenomas.
The mechanism for 99mTc-MIBI uptake and washout
in pituitary adenomas is not clear. The uptake of
99mTc-MIBI depends on the distribution of regional
blood flow and on mitochondrial oxidation capacity,
which is an indicator of cell viability (17, 26, 27). In
addition, 99mTc-MIBI SPECT is known as capability
of predicting patient's response to chemotherapy
in cases of malignant tumors because decreased
accumulation of 99mTc-MIBI implies the presence
of Pgp, which also transports chemotherapeutic
agents outward from the tumor cell (9, 28-32). In
gliomas, Andrews et al .(33) found the correlation
between 99mTc-MIBI SPECT findings and MDR-1
gene expression in 6 glioma cases, and they
supported the use of 99mTc-MIBI SPECT as a non-
invasive method for detecting MDR-1 gene ex-
pression in gliomas. On the other hands, Shibata
et al .(34) reported that Pgp expression of both
tumor cells and vascular endothelial cells showed
no correlation with 99mTc-MIBI SPECT findings in
26 gliomas. To date, however, little has been known
about the relationship between the expression of
Pgp and 99mTc-MIBI SPECT findings in pituitary
adenomas (24, 25). Pgp or MRP expression in pi-
tuitary adenomas has not been reported in the lit-
erature. Our study revealed that Pgp was ex-
pressed in 6 of 15 (40%) pituitary adenomas, and
two of 5 (40%) cases showed MDR-1 mRNA over-
expression by RT-PCR assay. There seems to be
correlation between these two data. Our study also
revealed that the RI on 99mTc-MIBI SPECT corre-
lated significantly with Pgp expression. These re-
sults indicate that Pgp, an MDR-1 gene product,
contributes as a washout mechanism of 99mTc-MIBI
in pituitary adenomas.
In this study, the washout rate was defined as
the difference in uptake ratio between 15 min. and
3 hrs after injection of 99mTc-MIBI. It is not known
whether the Pgp-mediated transport of radioactiv-
ity is a rapidly functioning mechanism or not, such
that Pgp transport is already completed within 15
min after injection of 99mTc-MIBI. It has recently
been reported that 99mTc-MIBI is a substarte not
only for Pgp but also for multidrug resistance as-
sociated protein (MRP)(11). The retention of 99mTc-
MIBI in cells might depend on both Pgp and MRP
expression, therefore further studies with simulta-
neous measurement of MRP expression in pitui-
tary adenomas are also necessary. Neither MDR-1
(Pgp) nor MRP expression in pituitary adenomas
have been reported in the literature.
Though pituitary adenomas are generally a clini-
cally benign tumor, some of tumor recur and de-
velop invasion. It is therefore important to predict
aggressive behavior. Although the number of pa-
tients in the present study was small, we believe
that 99mTc-MIBI SPECT may not be available in de-
termining the proliferative potential or invasion.
Then, the washout mechanism of 99mTc-MIBI may
be associated with the Pgp expression in pituitary
adenomas.
Table 3. Comparison of 99 mTc-MIBI findings in the Pgp
positive and negative groups
99mTc-MIBI -SPECT
ER DR RI (%)
Pgp positive group
(n=6)
Pgp negative group
(n=9)
47.34±49.82
56.13±58.68
27.50±32.55
41.57±34.00
‐38.55±20.77＊
‐15.78±19.40＊
Values are mean±standard deviation. ER : early uptake ratio,
DR : delayed uptake ratio, RI : retention index
Pgp : P-glycoprotein,
99mTc-MIBI-SPECT : technetium-99 m-methoxyisobutylisonitrile
single photon emission computed tomography
＊Significance difference between Pgp positive and negative
groups (Student’s t-test, p<0.05)
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